A Phase 2 interventional study of Placebo and Cemdisiran in IgA Nephropathy (IgAN), Berger Disease and Glomerulonephritis, IgA, sponsored by Alnylam Pharmaceuticals. Terminated at 17 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by Alnylam Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Glomerulonephritis, IGA with a site in Canada — 4 open to participants now, 11 under way, 10 of them phase 3. Glomerulonephritis, IGA · Canada.
Among the 22 studies in Glomerulonephritis, IGA with a site in Canada, this one is the 19th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2019, is one of 5 in phase 2, and was the 5th registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.
Browse Glomerulonephritis, IGA studies →4 of the 22 studies in Glomerulonephritis, IGA with a site in Canada are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Canada, United States, Argentina and 6 more countries
Ages 18–100
Biogen · Sites in Canada, United States, Argentina and 25 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Canada, United States, Argentina and 33 more countries
Ages 18–100
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in Canada, United States, Argentina and 28 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 14
First in 2009; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 383 across the 21 interventional studies, 211 across the 1 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 22 have an industry lead sponsor. The 10 most frequent:
Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.
Alnylam Pharmaceuticals has 1 study filed under Glomerulonephritis, IGA — fewer than ten, so there is no comparison to draw.
2 of the studies in Glomerulonephritis, IGA with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06935357Phase 3BiogenA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | 2027-05-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Glomerulonephritis, IGA with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). These participants are at high risk for progression of kidney disease, which can result in end-stage renal failure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received cemdisiran, 600 milligrams (mg), subcutaneous (SC) injection, once every 4 weeks (Q4W) in combination with standard of care treatment up to a maximum of 38 weeks in the DBT period.
Drug: Cemdisiran
Participants received cemdisiran matching placebo, SC injection, Q4W in combination with standard of care treatment up to a maximum of 38 weeks in the DBT period.
Drug: Placebo
Participants who were randomized to receive cemdisiran in the DBT period continued receiving cemdisiran, 600 mg, SC injection, Q4W in combination with standard of care treatment up to a maximum of 88 weeks in the OLE treatment period.
Drug: Cemdisiran
Participants who were randomized to receive cemdisiran matching placebo in the DBT period started receiving cemdisiran, 600 mg, SC injection, Q4W in combination with standard of care treatment up to a maximum of 88 weeks in the OLE treatment period.
Drug: Cemdisiran
Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
Cemdisiran was administered by SC injection.
Also known as: ALN-CC5
Percent Change From Baseline in UPCR as Measured in 24-hour Urine at Week 32
UPCR is a way of assessing the amount of protein in the urine. The primary analysis for UPCR was performed using Mixed-Effect Model Repeated Measures (MMRM) approach. Geometric mean (GM)ratios were obtained by exponentially back-transforming the arithmetic mean of change in log-transformed 24h UPCR. Standard error of the mean (SEM) was calculated as exponential (mean of change in log-transformed data) \* (standard error of change in log-transformed data). Adjusted GM ratio to baseline and 90% confidence interval (CIs) were calculated by exponentially back-transforming the model-based least square (LS) mean and the corresponding 90% CI.
Time frame: Baseline to Week 32
Percent Change From Baseline in 24-hour Proteinuria at Week 32
Proteinuria is high levels of protein in the urine. 24-hour proteinuria assessment included 24-hour urine collections to assess total protein excretion per 24 hours. Analysis was performed using the MMRM model. GM ratios were obtained by exponentially back-transforming the arithmetic mean of change in log-transformed 24h urine protein (UP). SEM was calculated as exp (mean of change in log-transformed data) \*(standard error of change in log-transformed data). Adjusted GM ratio to baseline and 90% CIs are calculated by exponentially back-transforming the model-based LS Means and the corresponding 90% CI.
Time frame: Baseline to Week 32
Percentage of Participants With Partial Clinical Remission at Week 32
Partial clinical remission was defined as having UP \<1.0 g/24-hours.
Time frame: Week 32
Percentage of Participants With >50% Reduction in 24-hour Proteinuria at Week 32
Time frame: Week 32
Change From Baseline in UPCR as Measured in a Spot Urine at Week 32
UPCR was calculated by dividing the level of protein in a spot urine test by the creatinine level. Analysis was performed using MMRM model. GM ratios were obtained by exponentially back-transforming the arithmetic mean of change in log-transformed spot UPCR. SEM was calculated as exp (mean of change in log-transformed data) \*(standard error of change in log-transformed data). Adjusted GM ratio to baseline and 90% CIs are calculated by exponentially back-transforming the model-based LS Means and the corresponding 90% CI.
Time frame: Baseline to Week 32
Number of Participants With Change From Baseline in Hematuria at Week 32
Hematuria is the presence of blood in the urine. Hematuria from spot urine collections was evaluated to assess the effect of cemdisiran on disease course in participants. The degree of hematuria was assessed by microscopic examination of the spun urine sediment (red blood cell (RBC)/ high power field \[hpf\]) and by urine dipstick.
Time frame: Baseline to Week 32
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Time frame: Up to 126 weeks
Participants were enrolled in the study at 19 investigative centers in Canada, France, Malaysia, Philippines, Singapore, Spain, Sweden, Taiwan, and the United Kingdom from 30 Sept 2019 to 27 June 2023.
| Milestone | DBT Period: Placebo | DBT Period: Cemdisiran | DBT Period: Placebo to OLE Period: Cemdisiran | DBT Period: Cemdisiran to OLE Period: Cemdisiran |
|---|---|---|---|---|
| Started | 9 | 22 | 0 | 0 |
| Modified intent-to-treat (mitt) analysis set | 9 | 22 | 0 | 0 |
| Completed | 8 | 21 | 0 | 0 |
| Not completed | 1 | 1 | 0 | 0 |
| Withdrew: Death | 1 | 1 | 0 | 0 |
| Milestone | DBT Period: Placebo | DBT Period: Cemdisiran | DBT Period: Placebo to OLE Period: Cemdisiran | DBT Period: Cemdisiran to OLE Period: Cemdisiran |
|---|---|---|---|---|
| Started | 0 | 0 | 8 | 20 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 8 | 20 |
| Withdrew: Adverse event | 0 | 0 | 1 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 | 3 |
| Withdrew: Study termination by sponsor | 0 | 0 | 4 | 9 |
| Withdrew: Other reason not specified | 0 | 0 | 2 | 5 |
UPCR is a way of assessing the amount of protein in the urine. The primary analysis for UPCR was performed using Mixed-Effect Model Repeated Measures (MMRM) approach. Geometric mean (GM)ratios were obtained by exponentially back-transforming the arithmetic mean of change in log-transformed 24h UPCR. Standard error of the mean (SEM) was calculated as exponential (mean of change in log-transformed data) \* (standard error of change in log-transformed data). Adjusted GM ratio to baseline and 90% confidence interval (CIs) were calculated by exponentially back-transforming the model-based least square (LS) mean and the corresponding 90% CI.
| percent change | DBT Period: Placebo | DBT Period: Cemdisiran |
|---|---|---|
| Percent Change From Baseline in UPCR as Measured in 24-hour Urine at Week 32 | 1.095 ± 0.258 | 0.686 ± 0.098 |
Proteinuria is high levels of protein in the urine. 24-hour proteinuria assessment included 24-hour urine collections to assess total protein excretion per 24 hours. Analysis was performed using the MMRM model. GM ratios were obtained by exponentially back-transforming the arithmetic mean of change in log-transformed 24h urine protein (UP). SEM was calculated as exp (mean of change in log-transformed data) \*(standard error of change in log-transformed data). Adjusted GM ratio to baseline and 90% CIs are calculated by exponentially back-transforming the model-based LS Means and the corresponding 90% CI.
| percent change | DBT Period: Placebo | DBT Period: Cemdisiran |
|---|---|---|
| Percent Change From Baseline in 24-hour Proteinuria at Week 32 | 1.051 ± 0.266 | 0.671 ± 0.104 |
Partial clinical remission was defined as having UP \<1.0 g/24-hours.
| percentage of participants | DBT Period: Placebo | DBT Period: Cemdisiran |
|---|---|---|
| Percentage of Participants With Partial Clinical Remission at Week 32 | 0 | 22.7 |
| percentage of participants | DBT Period: Placebo | DBT Period: Cemdisiran |
|---|---|---|
| Percentage of Participants With >50% Reduction in 24-hour Proteinuria at Week 32 | 0 | 22.7 |
UPCR was calculated by dividing the level of protein in a spot urine test by the creatinine level. Analysis was performed using MMRM model. GM ratios were obtained by exponentially back-transforming the arithmetic mean of change in log-transformed spot UPCR. SEM was calculated as exp (mean of change in log-transformed data) \*(standard error of change in log-transformed data). Adjusted GM ratio to baseline and 90% CIs are calculated by exponentially back-transforming the model-based LS Means and the corresponding 90% CI.
| gram per gram (g/g) | DBT Period: Placebo | DBT Period: Cemdisiran |
|---|---|---|
| Change From Baseline in UPCR as Measured in a Spot Urine at Week 32 | 1.344 ± 0.139 | 0.729 ± 0.109 |
Hematuria is the presence of blood in the urine. Hematuria from spot urine collections was evaluated to assess the effect of cemdisiran on disease course in participants. The degree of hematuria was assessed by microscopic examination of the spun urine sediment (red blood cell (RBC)/ high power field \[hpf\]) and by urine dipstick.
| Participants | DBT Period: Placebo | DBT Period: Cemdisiran |
|---|---|---|
| Post-Baseline Category: Negative | 0 | 4 |
| Post-Baseline Category: Small | 2 | 11 |
| Post-Baseline Category: Moderate | 2 | 4 |
| Post-Baseline Category: Large | 4 | 1 |
An AE is any untoward medical occurrence in a participant or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
| Participants | DBT Period: Placebo | DBT Period: Cemdisiran | DBT Period: Placebo + OLE Period: Cemdisiran | DBT Period: Cemdisiran + OLE Period: Cemdisiran | All Cemdisiran |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 8 | 19 | 8 | 22 | 30 |
Collected over DBT Period: from the first dose of study drug up to 38 weeks. OLE Period: from Week 38 up to 88 weeks (up to 126 weeks for both periods combined). All Cemdisiran: from the first dose of study drug up to 126 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DBT Period: Placebo | 1/9 (11.1%) | 0/9 (0%) | 8/9 (88.9%) |
| DBT Period: Cemdisiran | 1/22 (4.5%) | 1/22 (4.5%) | 19/22 (86.4%) |
| DBT Period: Placebo + OLE Period: Cemdisiran | 0/8 (0%) | 3/8 (37.5%) | 8/8 (100%) |
| DBT Period: Cemdisiran + OLE Period: Cemdisiran | 1/22 (4.5%) | 2/22 (9.1%) | 22/22 (100%) |
| All Cemdisiran | 2/30 (6.7%) | 5/30 (16.7%) | 30/30 (100%) |
| Event | DBT Period: Placebo | DBT Period: Cemdisiran | DBT Period: Placebo + OLE Period: Cemdisiran | DBT Period: Cemdisiran + OLE Period: Cemdisiran | All Cemdisiran |
|---|---|---|---|---|---|
| Cardiopulmonary failureCardiac disorders | — | 1/1 | 0/1 | 1/22 | 1/30 |
| Cholecystitis acuteHepatobiliary disorders | 0/9 | 0/22 | 1/8 | 0/22 | 1/30 |
| HyponatraemiaMetabolism and nutrition disorders | 0/9 | 0/22 | 1/8 | 0/22 | 1/30 |
| End stage renal diseaseRenal and urinary disorders | 0/9 | 0/22 | 1/8 | 0/22 | 1/30 |
| Helicobacter gastritisInfections and infestations | 0/9 | 0/22 | 0/8 | 1/22 | 1/30 |
| Event | DBT Period: Placebo | DBT Period: Cemdisiran | DBT Period: Placebo + OLE Period: Cemdisiran | DBT Period: Cemdisiran + OLE Period: Cemdisiran | All Cemdisiran |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/9 | 2/22 | 5/8 | 9/22 | 14/30 |
| Injection site reactionGeneral disorders | 2/9 | 9/22 | 5/8 | 9/22 | 14/30 |
| Injection site recall reactionGeneral disorders | 0/9 | 2/22 | 3/8 | 2/22 | 5/30 |
| NasopharyngitisInfections and infestations | 3/9 | 0/22 | 1/8 | 0/22 | 1/30 |
| HyperphosphataemiaMetabolism and nutrition disorders | 0/9 | 0/22 | 2/8 | 0/22 | 2/30 |
| HypertensionVascular disorders | 1/9 | 0/22 | 2/8 | 1/22 | 3/30 |
| NauseaGastrointestinal disorders | 0/9 | 1/22 | 2/8 | 1/22 | 3/30 |
| PyrexiaGeneral disorders | 1/9 | 1/22 | 2/8 | 3/22 | 5/30 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/9 | 0/22 | 2/8 | 0/22 | 2/30 |
| Back painMusculoskeletal and connective tissue disorders | 2/9 | 0/22 | 1/8 | 1/22 | 2/30 |
Safety Analysis Set included all participants who received any amount of study drug.
| Age, Continuous(years) | DBT Period: Placebo | DBT Period: Cemdisiran | Total |
|---|---|---|---|
| Mean | 37.6 ± 10.4 | 40.5 ± 10.1 | 39.7 ± 10.1 |
| Sex: Female, Male(Participants) | DBT Period: Placebo | DBT Period: Cemdisiran | Total |
|---|---|---|---|
| Female | 6 | 9 | 15 |
| Male | 3 | 13 | 16 |
| Ethnicity (NIH/OMB)(Participants) | DBT Period: Placebo | DBT Period: Cemdisiran | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 4 |
| Not Hispanic or Latino | 7 | 18 | 25 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | DBT Period: Placebo | DBT Period: Cemdisiran | Total |
|---|---|---|---|
| Asian | 4 | 12 | 16 |
| White | 4 | 8 | 12 |
| Other | 0 | 1 | 1 |
| Not Reported | 1 | 1 | 2 |
| Urine Protein to Creatinine Ratio(g/g) | DBT Period: Placebo | DBT Period: Cemdisiran | Total |
|---|---|---|---|
| Mean | 1.972 ± 0.815 | 1.554 ± 1.032 | 1.676 ± 0.979 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Mar 2022, 29 months.
Results were first posted in Dec 2023, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemdisiran